News >

Research Abounds in Targeting Rare Mutations in Lung Cancer

Ellie Leick
Published: Friday, Nov 08, 2019

Michael D. Offin, MD

Michael D. Offin, MD

As the use of next-generation sequencing (NGS) in lung cancer increases, ongoing research is focusing on new therapeutics to target less-common mutations that can be identified, explained Michael D. Offin, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication